Azithromycin reaches high concentrations in phagocytic and other host cells, suggesting that they may transport this agent to specific sites of infection. Models of localized infection (Haemophilus influenzae middle ear infection in gerbils, Streptococcus pyogenes implanted contaminated paper disc and Streptococcus pnewnoniae pneumonia in mice) that induced severe inflammatory response after challenge were used to explore this hypothesis. Animals were given a single 100 or 50mg/kg po dose of azithromycin at various times from 2 to 120 h following introduction of a pathogen or sterile medium. When azithromycin was given during a period of little or no inflammation, there was marginal difference between concentrations found in infected or non-infected sites (bulla, disc, lung). However, when the compound was given during a period of inflammation, considerably higher drug concentrations were found in infected sites than in non-infected sites at 5-24 h after dosing (0.38-0.44 mg/c compared with 0.07-0.14 mg/L of bulla wash; 1.01-1.75 ng compared with =$0.01-0.03 fig at the disc site; 1.72-5.28 mg/kg compared with 0.7-1.53 mg/kg of lung). When the observation periods were extended to include 48, 56 or 96 h after dosing, the ratio of azithromycin infection site concentration: serum concentration steadily increased with time in all model systems (middle ear, implanted disc and pneumonia), reflecting the maintenance of concentrations at the sites of infection, while serum concentrations declined. Bioassay of cell pellets and supernatants, obtained from pooled bulla washes of gerbils treated with azithromycin during a period of inflammation, revealed that cellular components accounted for about 75% of the azithromycin detected. These data show that increased azithromycin concentrations occur at sites of localized infection. This correlates with the presence of inflammation and is associated with the cellular components of the inflammatory response. Therefore, phagocytes may be important vehicles for delivering azithromycin to and sustaining azithromycin concentrations at sites of infection.
Introduction
Azithromycin has been reported to be readily concentrated in polymorphonuclear leucocytes (PMNs) and macrophages (Gladue et al., 1989; Wildfeuer et al., 1989) . It has also been reported that phagocytic cells can transport intracellular azithromycin to localized sites of infection in response to caseinate stimulation (Gladue et al., 1989) . Since production of phagocytic cells also occurs as part of the normal host cellular response to infection, these observations suggest that phagocytes containing azithromycin may be important vehicles in the transport of drug to specific sites of infection. The studies reported here were designed to determine if azithromycin is preferentially distributed to infected compared with non-infected sites and to investigate the correlation of the inflammatory response and phagocyte infiltration with increased azithromycin concentrations. Determinations of the distribution of antibiotics within cellular versus fluid contents of washes taken from infected bullae were also made. Part of these results have been reported previously (Girard et al., 1990; Girard, Faiella & Cimochowski, 1991) .
Materials and methods

Antimicrobial agents
Azithromycin was obtained from the Process Research Department, Central Research Division, Pfizer Inc., Groton, USA. All other antimicrobials were obtained from their respective manufacturers. All compounds were given orally.
Bacterial strains
Haemophilus influenzae (Pfizer strain 54A131, /f-lactamase-positive; Pfizer strain 54A085, /Mactamase-negative for amoxycillin studies of distribution in bulla wash) strains were used in the intrabulla challenge of gerbils. Streptococcus pyogenes ATCC 12384 was employed in the mouse disc infection model. The Streptococcus pneumoniae strain used in the mouse model of pneumococcal pneumonia was a serotype 3 strain (P4241) obtained from Dr J.-J. Pocidalo, Hopital Claude Bernard, Institut National de la Sante et de la Recherche Medical, Paris, France.
Media and growth conditions
All organisms were grown in 5% CO 2 at 37°C. H. influenzae was grown in Brain Heart Infusion Broth (BHI) (Adams Scientific Inc., West Warwick, RI, USA) supplemented with 4% Fildes enrichment and 2% co-factor (Quiger Laboratory). S. pneumoniae was grown on BHI blood agar (containing 2.5% sheep RBCs) for the mouse lung infections model. The 5. pyogenes challenge was prepared by growing the organism in BHI broth.
Animals
The animals used were 18-20 g, mixed sex, outbred CF1 mice (5. pyogenes disc model) or female C57BL/6 mice (lung infection model) which were purchased from the Charles River Breeding Laboratories. Female Mongolian gerbils (45-50 g), purchased from Tumblebrook Farms, Brookfield, MA, USA, were used in the model of middle ear infection. Appropriate anaesthesia was administered to all animals before delivery of challenge. All experiments were performed in accordance with accepted Institutional Animal Care and Use Committee guidelines.
Models of infection
Gerbil middle ear infection. An inoculum of H. influenzae or sterile medium was delivered directly into the left bullae of anaesthetized (ketamine/xylazine) gerbils as previously described (Girard et al., 1987) .
For the initial studies, a single 50-mg/kg dose of azithromycin was given at 24, 48 or 72 h after challenge; samples of bulla wash from infected and non-infected gerbils were taken 5 h after dosing. After the initial studies, all later single-dose treatments were given 48 h after challenge and samples were taken up to 48 h after dosing. There were five samples/group in all studies.
Distribution of antibiotic in bulla washes. All compounds were given as single 100-mg/kg doses at 48 h after H. influenzae challenge. The sampling time after dosing varied depending on the compound; samples were taken at a time when the particular antibiotic had been shown to achieve a maximum concentration in the bullae in preliminary studies. Bulla washes (0.1 mL) taken from the right and left bullae of each gerbil were pooled. Microscopic examination of all washes showed numerous WBCs. Washes were centrifuged to separate the cellular components from the fluid components. Cell pellets were resuspended in sterile distilled water to the original volume and then subjected to a freeze-thaw technique. Supernatants and cell suspensions (freeze-thawed) were then bioassayed to determine antibiotic concentrations. Final values (n = 10/group) for the antibiotic concentrations were expressed as the percentage associated with the cell pellet or fluid.
Localized S. pyogenes infection. Sterile paper discs or discs containing S. pyogenes were implanted in the left mid-backs of anaesthetized (methoxyflurane) CF1 mice. A study was conducted to determine the distribution of azithromycin in infected and non-infected sites following a single oral dose (50 mg/kg) given at various periods after implantation of a sterile paper disc or one containing 5. pyogenes. A single 50-mg/kg dose of azithromycin was given at 2, 24, 32 or 48 h after challenge; animals were killed 24 h after dosing, discs/lesions removed and azithromycin concentrations determined by bioassay. In later studies, animals were treated once at 24 h after challenge and sampled up to 56 h after dosing. There were ten samples for each experimental group.
Mouse lung infection. S. pneumoniae pneumonia was induced in a manner similar to that described by Esposito & Pennington (1983) . Briefly, animals were anaesthetized (ip ketamine/xylazine) and the tracheas were surgically exposed. Each mouse was then infected by administering 0.03 mL of a log-phase culture directly into the trachea. The animals were maintained in a vertical position to facilitate distal alveolar migration of bacteria by gravity. A group of non-infected animals were prepared in the same fashion, but 0.03 mL of sterile BHI broth was placed in the trachea.
Initially, a single 50-mg/kg dose of azithromycin was given at 48, 72, 96 or 120 h after challenge or placebo; lung samples were obtained from treated infected and non-infected animals 24 h after dosing. After the initial studies, single 50-mg/kg doses were given at 96 h after challenge and samples were taken up to 56 h after dosing. There were three to five animals in each experimental group.
Bioassay of antibiotics
Samples of bulla wash, paper disc and lung were analysed by a modified agar well diffusion bioassay (Simon & Yin, 1970) with Micrococcus luteus ATCC 9341 as the indicator organism. Standard curves were prepared as appropriate in tissue homogenate or serum from non-treated animals. Seed agar was used for assay of amoxycillin and neomycin assay agar was used for all macrolides. The bioassay correlation coefficients (%) and limits of sensitivity for detection (mg/L) in bulla wash were as follows: azithromycin, 99.8% and 0.07 mg/L, respectively; erythromycin, 99.7% and 0.08 mg/L, respectively; roxithromycin, 99.9% and 0.14 mg/L, respectively; clarithromycin, 99.7% and 0.04 mg/L, respectively; and amoxycillin, 99.6% and 0.04 mg/L, respectively. The bioassay correlation coefficients and limits of sensitivity for detection of azithromycin in serum were 99.5% and 0.03 mg/L, respectively. The bioassay correlation coefficients and limits of sensitivity for detection of azithromycin in discs were 99.2% and 0.02 g/disc, respectively; the values for azithromycin in lung tissue were 99.9% and 0.35 mg/kg tissue, respectively.
Results
Middle ear infection
Middle ear washes taken from either infected or non-infected animals at 24 h after challenge were generally clear and relatively free of any phagocytes, as determined by direct microscopic observation. In contrast, washes taken from infected gerbils at 48 or 72 h after challenge were generally cloudy; microscopic examination showed the presence of numerous phagocytes, consistent with an inflammatory response. Washes taken at 48 or 72 h from sham-(sterile broth-) challenged gerbils remained clear and free of phagocytes.
Significant concentrations (P < 0.003) of azithromycin occurred only in middle ear washes taken from gerbils treated either 48 or 72 h after initiation of H. influenzae infection; lavages taken from animals treated 24 h after challenge with H. influenzae or those treated 24,48 or 72 h after receiving the sterile injection did not contain significant concentrations of azithromycin (Table I ). The serum concentrations in all samples were similar, but the ratios of bulla wash to serum concentration increased in the infected animals as a consequence of increased concentrations in the middle ear when treatment was given at 48 or 72 h after challenge (Table I) . One animal in the non-infected group, treated 72 h after injection of sterile medium, had significant concentrations of azithromycin in the middle ear, 5 h after dosing. This sample was also monitored bacteriologically and a heavy growth of a non-/?-haemolytic Streptococcus sp. was isolated. Apparently this was a saprophyte that was introduced inadvertently into the bulla, resulting in infection and an inflammatory response.
In an additional study, gerbils infected with H. influenzae and treated with a single oral dose of azithromycin 48 h after infection were monitored for an extended period "Pooled sample from five animals. *Bulla washes from five different animals during each sample period were independently assayed; mean ± S.E M of up to 48 h after dosing, compared with the earlier study in which sampling took place only 5 h after a dose. The bulla concentrations were shown to increase from 2 to 24 h following a dose and were maintained for up to 48 h after dosing (Table II) . In contrast, the highest serum concentration was observed at 2 h after a dose, declining by 4 h, with a plateau between 4 and 6 h, and followed by a sustained decline 24 and 48 h after treatment. The steady decline in serum concentrations, coupled with the steady increase of bulla concentrations over this period, expressed as a steady increase in the ratio of bulla to serum concentration from 2 to 48 h after dosing.
Distribution of antibiotics in bulla washes
Azithromycin was extensively (75%) associated with the cellular component of the bulla wash (Table III) , while amoxycillin was almost entirely (95%) associated with the fluid component. Amoxycillin served as a control in this study, since penicillins are recognized as penetrating poorly into host cells. Erythromycin, roxithromycin and clarithromycin were largely (about 70%) associated with the fluid; only about 30% was found in the cell pellet. The association of the macrolides with cellular components at this site of infection is considerably less than that seen with azithromycin. 
Localized S. pyogenes infection
Between 24 and 48 h after implantation, a significant lesion formed beneath and around the paper disc containing S. pyogenes. Material taken from this lesion and examined microscopically revealed the presence of PMNs and monocytes containing S. pyogenes. Eventually, this infection resolved spontaneously after 3-5 days by draining and, in some cases, expelling the disc to the surface, followed by rapid healing. When azithromycin was given shortly after implantation (2 h after infection), there was no significant difference between the azithromycin concentrations at infected and non-infected sites (Table IV) . Thirty-to 175-fold increases in azithromycin concentrations were found in infected compared with non-infected sites when animals were dosed at 24, 32 or 48 h after challenge.
In an additional study, mice infected with S. pyogenes and treated with a single oral dose of azithromycin 24 h after infection were monitored for periods of up to 56 h after dosing, compared with the earlier study when sampling was carried out only at 24 h after dosing. The disc concentrations were shown to increase from 2 to 8 h following a dose and were maintained for up to 56 h after dosing (Table V) . The highest serum concentration was observed at 1-2 h after dosing, declining by 4 h, with a plateau between 4-8 h, and followed by a sustained decline 24-56 h after treatment. The steady decline in serum concentrations, coupled with the steady increase in disc 
Lung infection
Concentrations of azithromycin found in the lungs of non-infected mice showed no significant difference when dosed 48-120 h after the administration of sterile broth (Table VI) . There was also no significant difference between the lung concentrations measured in infected and non-infected mice when the dose was given at 48 or 72 h after delivery of the challenge or sterile broth. Compared with non-infected mice, significantly (P < 0.02) higher concentrations of antibiotic (four-to seven-fold) were observed in lungs taken from infected animals dosed at 96 or 120 h after challenge. The azithromycin concentrations detected in infected lungs following dosing at 96 and 120 h after challenge were not significantly different. These studies were extended to include longer periods of sampling following a single dose given at 96 h after challenge with S. pneumoniae. Infected and treated mice were monitored for a period of up to 56 h after dosing, compared with the earlier study in which sampling was undertaken only 24 h after dosing. The lung concentrations increased from 1 to 24 h after dosing and were maintained for up to 48 h after dosing (Table VII) . The highest serum concentration was observed at 4 h after dosing, declining at 8 h and followed by a sustained decline at 24-56 h after treatment. The decline in serum concentrations, coupled with the increase in lung concentrations over this period, was expressed as a steady increase in the lung to serum concentration ratios from 8 to 32 h and maintenance for up to 56 h following dosing.
Discussion
The concentrations of azithromycin in middle ear fluid correlated directly with the presence of inflammation, i.e. infection alone at 24 h was not sufficient to enhance the azithromycin concentration and significant concentrations of azithromycin were found only after the appearance of WBCs in the bullae. Serum concentrations in infected and non-infected animals were not significantly different and therefore not obviously influenced by the presence of infection or inflammation. Furthermore, when the observation periods were extended to 24 and 48 h after dosing, elevated concentrations of azithromycin were maintained in bulla washes, while the serum concentrations declined.
The studies of the distribution of antibiotic within bulla washes taken from H. influenzae-infecled gerbils provides further support for the hypothesis that the cellular components of the inflammatory response contribute significantly to the concentration of azithromycin at the site of infection. While the cellular components remain in the bullae, they probably contribute to the prolonged maintenance of azithromycin concentrations at this site. In contrast to the results obtained with azithromycin, the data suggest that the fluid component of the inflammatory response contributes significantly to the bulla concentrations of erythromycin, roxithromycin and clarithromycin (Table III) . The high proportions of these drugs in the fluid component of the bulla washes are presumably a result of the rapid egress from the inflammatory cells, as observed in vitro (Gladue et al., 1989) . Therefore, their persistence in the bullae may correlate more closely with serum concentrations.
The data obtained from the gerbil model of middle ear infection are particularly meaningful since they correlate very well with studies conducted with children suffering from acute or secretory otitis media (Pukander, 1994) . Azithromycin was reported to penetrate into the middle ear very well, yielding plasma:effusion ratios of 1:78 at 12 h and 1:355 at 48 h following administration of a single 10 mg/kg oral dose to children with secretory otitis media, while plasma:effusion ratios of 1:200 and 1:363 were obtained at 24 and 48 h after completion of a 5-day (30 mg/kg total dosage) oral regimen by children with acute otitis media. One conclusion from these human studies is that azithromycin concentrations, despite being low in plasma, are elevated in children with acute or secretory otitis media.
In the S. pyogenes localized infection model, the highest concentration of azithromycin was measured when treatment was given at 24 h after challenge. Lower concentrations were detected when dosing was given at 32 or 48 h after challenge (Table IV) , possibly a period during which there was a decline in the inflammatory response which was followed by the healing process. The lowest concentrations were observed when the animals were dosed shortly after implantation, a time considerably before any visible signs of inflammation. In fact, dosing at this time prevented the formation of the lesion and the obvious inflammatory response. When the observation periods were extended to 32, 48 and 56 h following a dose, a pattern which was similar to that noted for the middle ear infection was noted, i.e. concentrations of azithromycin at the site of infection were elevated and maintained for a prolonged period while the serum concentrations declined.
Phagocytes are expected to accumulate substantial concentrations of azithromycin following oral dosing of azithromycin, as shown in humans, rats and dogs (Baldwin et al., 1990; Shepard & Gregoire, 1990) . If the drug is administered at a time when phagocytes are assumed to be migrating via chemotaxis (in the case of the S. pyogenes infection, 24 h after challenge), azithromycin concentrations at the infection site would be expected to increase as the azithromycin-containing WBCs arrive and remain at this site.
A recent report showed azithromycin concentrations to be significantly higher in human inflammatory blisters induced with autologous serum than in non-inflammatory blisters at 7-14 days following dosing (Freeman et al., 1994) . The inflammatory blisters contained a mean WBC count of 12,400/mm 3 which was four-to five-fold greater than that found in non-inflammatory blisters. The authors concluded that these data provided additional evidence that azithromycin is concentrated in PMNs and, as a result, may provide a unique physiological drug delivery system which allows this agent to reach the site of an infection. The results of the studies with the S. pyogenes model of localized infection are consistent with this scenario. The data presented here provide yet another example of the preferential distribution of azithromycin at an infection site and the association of this distribution with the cellular components of the host defence system.
The pneumococcal model of infection presented a pathological picture of a multifocal, acute suppurative bronchopneumonia ranging in severity from minimal at 24 h, to moderate at 48-72 h and to moderate-to-severe by 96 h after challenge. Pleurisy was seen at times, probably as a consequence of the challenge occasionally entering the pleural cavity through the outside of the trachea. Some inflammatory reactions were seen as early as 24 h and increased with time. By 96 h after challenge, there was clear participation by the inflammatory response, yielding multifocal pockets of pus, i.e. areas packed with phagocytes. These data are similar to those described in the histological studies of Azoulay-Dupuis et al. (1991a) .
The pneumococcal model of infection, therefore, simulated a disease that increased in severity as a function of time and included a severe inflammatory response occurring by 96 h after challenge. A less severe expression of disease with little inflammation occurred at 48-72 h after challenge. When azithromycin was given at 48-72 h after challenge, lung concentrations were not significantly different from those noted in non-infected mice. However, increased lung concentrations of azithromycin were observed when the disease and inflammation became more intense at 96 h. reported similar increases in lung azithromycin concentrations in S. pneumoniae-infected mice compared with non-infected mice. Their studies were focused primarily on efficacy, but they did show a higher C™, and area under the concentration versus time curve (AUC) for azithromycin in infected mice compared with non-infected mice. They concluded that the maintenance and possible enhancement of azithromycin lung concentrations in infected mice compared with non-infected animals could explain the greater efficacy of azithromycin relative to erythromycin in their model of pneumonia.
When the observation periods of the current studies were extended to 56 h after dosing, the increase in azithromycin concentrations associated with inflammation became more obvious as the lung to serum ratios steadily increased and was maintained for up to 56 h after dosing. The work of Vallee et al. (1992) is also consistent with these data. They noted a four-fold increase in azithromycin AUC and a maintenance of detectable azithromycin concentrations for long periods in the lungs of H. influenzae-infected mice compared with non-infected animals. In addition to reporting that phagocytes achieved increased concentrations of azithromycin at the site infection, these investigators suggested that active intracellular concentrations of azithromycin were provided by release of the antibiotic from PMNs, since efficacy coincided with the arrival of large numbers of these cells.
The results our studies with the S. pneumoniae model of lung infection are consistent and corroborate those obtained earlier with the middle ear and disc models of localized infection and their associated inflammatory responses. In addition, the data obtained with the mouse pneumonia model correlated well with recent findings from human studies. Ballow et al. (1995) reported on the concentrations of azithromycin in human peripheral PMNs and estimated the concentrations achieved within the cells at the site of infection following a 5-day oral regimen. Their data suggested that respiratory tract infection sites with 10 7 WBC/mL would achieve total azithromycin concentrations of 2-3 mg/L and intracellular concentrations in excess of 100 mg/L. They concluded that accumulation of azithromycin within PMNs, followed by migration of the PMNs to sites of infection, would yield clinically significant local tissue concentrations.
The data presented here were obtained from three models of localized infection, representing three different sites (bulla, implanted disc and lung) and three different pathogens (H. influenzae, S. pyogene.i and S. pneumoniae). All of these data provide a consistent picture of the increased concentrations of azithromycin at infected compared with non-infected sites and a correlation with phagocytic infiltration. These studies and those reported by Azoulay-Dupuis et al. (19916) , Vallee et al. (1992) and others also support the thesis that host phagocytes may be important contributors to the delivery and maintenance of increased concentrations of azithromycin at infected compared with non-infected sites.
